Inhibrx 11/9/2023 Earnings Report

Inhibrx EPS Results

• Actual EPS: -$1.10
• Consensus EPS: -$1.01
• Beat/Miss: Missed by -$0.09
• One Year Ago EPS: N/A

Inhibrx Revenue Results

• Actual Revenue: $0.12 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Inhibrx Announcement Details

• Date: 11/9/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Inhibrx (NASDAQ:INBX), a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.